PharmaCyte Biotech (PMCB) Long-Term Deferred Tax (2012 - 2025)
PharmaCyte Biotech (PMCB) posted quarterly Long-Term Deferred Tax of $16.9 million for Q2 2025, up 4.18% year-over-year from $16.2 million in Q2 2024, and up 4.18% quarter-over-quarter from $16.2 million in Q2 2024.
PharmaCyte Biotech (PMCB) Long-Term Deferred Tax (2012 - 2025) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Long-Term Deferred Tax for 11 consecutive years, with $16.9 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Long-Term Deferred Tax rose 4.18% year-over-year to $16.9 million; the TTM figure through Apr 2025 stood at $16.9 million (up 4.18% YoY), while the FY2025 annual figure was $16.9 million, up 4.18% from the prior year.
- Long-Term Deferred Tax grew to $16.9 million in Q2 2025 per PMCB's latest filing, from $16.2 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $16.9 million in Q2 2025 and bottomed at $4.2 million in Q4 2023.
- Historically, Long-Term Deferred Tax has averaged $10.5 million across 3 years, with a median of $10.4 million in 2023.
- On a YoY basis, Long-Term Deferred Tax climbed as much as 4.18% in 2025 and fell as far as 4.18% in 2025.
- PharmaCyte Biotech's Long-Term Deferred Tax stood at $4.2 million in 2023, then surged by 284.74% to $16.2 million in 2024, then rose by 4.18% to $16.9 million in 2025.
- Business Quant data shows PMCB's Long-Term Deferred Tax at $16.9 million in Q2 2025, $16.2 million in Q2 2024, and $4.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | 16.91 Mn |
| Apr 30, 2024 | 16.24 Mn |
| Oct 31, 2023 | 4.22 Mn |
| Jul 31, 2023 | 4.55 Mn |
| Apr 30, 2019 | 14.19 Mn |
| Apr 30, 2018 | 13.24 Mn |
| Apr 30, 2017 | 11.52 Mn |
| Apr 30, 2016 | 10.25 Mn |
| Apr 30, 2015 | 13.13 Mn |
| Apr 30, 2014 | 12.82 Mn |
| Apr 30, 2013 | 12.46 Mn |
| Apr 30, 2012 | 12.20 Mn |